BeiGene, Ltd. is shifting to a combination therapy strategy for its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), the recently Shanghai-listed Chinese firm said.
BeiGene Switches To Combo Therapy Approach For Brukinsa
BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.
